Hi, today we are going to talk about Epizyme and its current landscape.
Epizyme is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company received unanimous approval from the FDA for its cancer drug Tazemetostat for the treatment of patients with epithelioid sarcoma. Amid the simmering of the Cancer Drug Race, with the sector hitting $5.2 billion in M&A deals, putting this news for Epizyme at a higher level for the company and push its shares to a higher level.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.